Combination celecoxib and temozolomide in C6 rat glioma orthotopic model

Seok-Gu Kang, Jong Soo Kim, Kwan Park, Jong Sung Kim, Morris D. Groves, Do Hyun Nam

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model. After stereotactic injection of C6/LacZ rat glioma cells into the Sprague Dawley rat brain, the rats were randomly assigned to four treatment groups [group 1, control treatment; group 2, celecoxib (25 mg/kg p.o. everyday) alone; group 3, temozolomide (7.5 mg/kg i.p. for 5 days at 2nd week) alone; group 4, a combination of celecoxib and temozolomide]. Rats were sacrificed 18 days after treatment, and the body weight, tumor volume, tumor cell proliferation, microvessel densities, and apoptosis were evaluated. There was a significant reduction of tumor volume in combination group compared to control or single-agent therapy. The median tumor volume was estimated to be 111.5 mm 3(control), 65.0 mm3(celecoxib), 71.8 mm 3(temozolomide) and 18.7 mm3(combination). In the combination group, there was increased tumor cell apoptosis as well as decreased microvessel density and tumor cell proliferation relative to the control and single-agent therapy (P<0.05). Collectively, the data suggest that the combination celecoxib and temozolomide may provide a novel and effective approach to the treatment of glioblastoma.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalOncology Reports
Volume15
Issue number1
Publication statusPublished - 2006 Jan 1

Fingerprint

Celecoxib
temozolomide
Glioma
Tumor Burden
Microvessels
Therapeutics
Cell Proliferation
Apoptosis
Neoplasms
Glioblastoma
Sprague Dawley Rats

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kang, S-G., Kim, J. S., Park, K., Kim, J. S., Groves, M. D., & Nam, D. H. (2006). Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncology Reports, 15(1), 7-13.
Kang, Seok-Gu ; Kim, Jong Soo ; Park, Kwan ; Kim, Jong Sung ; Groves, Morris D. ; Nam, Do Hyun. / Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. In: Oncology Reports. 2006 ; Vol. 15, No. 1. pp. 7-13.
@article{4d769cc7eab647aa9229f7d565479d6d,
title = "Combination celecoxib and temozolomide in C6 rat glioma orthotopic model",
abstract = "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model. After stereotactic injection of C6/LacZ rat glioma cells into the Sprague Dawley rat brain, the rats were randomly assigned to four treatment groups [group 1, control treatment; group 2, celecoxib (25 mg/kg p.o. everyday) alone; group 3, temozolomide (7.5 mg/kg i.p. for 5 days at 2nd week) alone; group 4, a combination of celecoxib and temozolomide]. Rats were sacrificed 18 days after treatment, and the body weight, tumor volume, tumor cell proliferation, microvessel densities, and apoptosis were evaluated. There was a significant reduction of tumor volume in combination group compared to control or single-agent therapy. The median tumor volume was estimated to be 111.5 mm 3(control), 65.0 mm3(celecoxib), 71.8 mm 3(temozolomide) and 18.7 mm3(combination). In the combination group, there was increased tumor cell apoptosis as well as decreased microvessel density and tumor cell proliferation relative to the control and single-agent therapy (P<0.05). Collectively, the data suggest that the combination celecoxib and temozolomide may provide a novel and effective approach to the treatment of glioblastoma.",
author = "Seok-Gu Kang and Kim, {Jong Soo} and Kwan Park and Kim, {Jong Sung} and Groves, {Morris D.} and Nam, {Do Hyun}",
year = "2006",
month = "1",
day = "1",
language = "English",
volume = "15",
pages = "7--13",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

Kang, S-G, Kim, JS, Park, K, Kim, JS, Groves, MD & Nam, DH 2006, 'Combination celecoxib and temozolomide in C6 rat glioma orthotopic model', Oncology Reports, vol. 15, no. 1, pp. 7-13.

Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. / Kang, Seok-Gu; Kim, Jong Soo; Park, Kwan; Kim, Jong Sung; Groves, Morris D.; Nam, Do Hyun.

In: Oncology Reports, Vol. 15, No. 1, 01.01.2006, p. 7-13.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination celecoxib and temozolomide in C6 rat glioma orthotopic model

AU - Kang, Seok-Gu

AU - Kim, Jong Soo

AU - Park, Kwan

AU - Kim, Jong Sung

AU - Groves, Morris D.

AU - Nam, Do Hyun

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model. After stereotactic injection of C6/LacZ rat glioma cells into the Sprague Dawley rat brain, the rats were randomly assigned to four treatment groups [group 1, control treatment; group 2, celecoxib (25 mg/kg p.o. everyday) alone; group 3, temozolomide (7.5 mg/kg i.p. for 5 days at 2nd week) alone; group 4, a combination of celecoxib and temozolomide]. Rats were sacrificed 18 days after treatment, and the body weight, tumor volume, tumor cell proliferation, microvessel densities, and apoptosis were evaluated. There was a significant reduction of tumor volume in combination group compared to control or single-agent therapy. The median tumor volume was estimated to be 111.5 mm 3(control), 65.0 mm3(celecoxib), 71.8 mm 3(temozolomide) and 18.7 mm3(combination). In the combination group, there was increased tumor cell apoptosis as well as decreased microvessel density and tumor cell proliferation relative to the control and single-agent therapy (P<0.05). Collectively, the data suggest that the combination celecoxib and temozolomide may provide a novel and effective approach to the treatment of glioblastoma.

AB - The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model. After stereotactic injection of C6/LacZ rat glioma cells into the Sprague Dawley rat brain, the rats were randomly assigned to four treatment groups [group 1, control treatment; group 2, celecoxib (25 mg/kg p.o. everyday) alone; group 3, temozolomide (7.5 mg/kg i.p. for 5 days at 2nd week) alone; group 4, a combination of celecoxib and temozolomide]. Rats were sacrificed 18 days after treatment, and the body weight, tumor volume, tumor cell proliferation, microvessel densities, and apoptosis were evaluated. There was a significant reduction of tumor volume in combination group compared to control or single-agent therapy. The median tumor volume was estimated to be 111.5 mm 3(control), 65.0 mm3(celecoxib), 71.8 mm 3(temozolomide) and 18.7 mm3(combination). In the combination group, there was increased tumor cell apoptosis as well as decreased microvessel density and tumor cell proliferation relative to the control and single-agent therapy (P<0.05). Collectively, the data suggest that the combination celecoxib and temozolomide may provide a novel and effective approach to the treatment of glioblastoma.

UR - http://www.scopus.com/inward/record.url?scp=33644877367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644877367&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 7

EP - 13

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -

Kang S-G, Kim JS, Park K, Kim JS, Groves MD, Nam DH. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncology Reports. 2006 Jan 1;15(1):7-13.